Avner Mandelman of Toronto, who advises on investments, published a book on the subject with McGraw Hill, and then looked into the firm as an investment opportunity.
“It soon dawned on me,” he writes in his Globe & Mail column, “that …the company has much of its R&D product development done for it at a relatively low cost by outside suppliers (authors) who are paid royalties only if they produce, so much of the product cost is variable. I like that.”
Well, as an investor he liked it….